To confirm the significance of CD39+ Treg cells in progression of BPH, mice were injected intraperitoneally with CD39 activity inhibitor polyoxometalate‐1 (POM‐1) before and after testosterone propionate administration. The gene discussed is ENTPD1; the disease is benign prostatic hyperplasia.